Industry News

Tata Global Beverages' China operations. Tata Group chairman Cyrus Mistry on Wednesday indicated that Tata Global Beverages might sell its loss-making Chinese subsidiary, reported Times of India."/>
Deals Buzz: Tata Global Beverages may sell Chinese subsidiary [Mint, New Delhi]
Zealand's interim report for the first half of 2016 (unaudited)
Aurobindo Pharma Ltd's share rose 7% on Wednesday, reacting to its June quarter results. The spike was somewhat surprising, as its sales growth and improvement in profitability was not unexpected. Perhaps, Aurobindo's ability to hit the target at a time when front line pharmaceutical companies are finding the going difficult is being rewarded."/>
Aurobindo Pharma: high expectations [Mint, New Delhi]
Aurobindo Pharma Ltd on Wednesday said it plans to introduce at least 19 products, addressing a market size of $6.8 billion in the US. All the 19 products, including 16 oral and three injectables, were approved by US Food and Drug Administration and await launch as the company is faced with capacity constraints. Aurobindo said it is pinning its hopes on big launches such as heartburn pill esomeprazole or generic Nexium, broad spectrum antibiotic meropenem, acid..."/>
Aurobindo Pharma to launch 19 products in US [Mint, New Delhi]
AstraZeneca said Wednesday it will sell its small-molecule antibiotics business to Pfizer in a deal that could be worth $1.5 billion. Pfizer will get rights to some medicines in development and approved antibiotics, including Merrem to treat severe infections of the skin or stomach, Zinforo to treat complicated skin and soft tissue infections, and Zavicefta approved in the European Union for patients with serious bacterial infections. AstraZeneca will receive an..."/>
BRIEF: AstraZeneca sells off drugs to Pfizer [The Philadelphia Inquirer]
Pfizer Inc. executive who also is on the Preston school board, said he expects to fill the position for six to nine months as SeCTer seeks a permanent replacement."/>
Preston Redevelopment Agency chairman takes helm at SeCTer [The Day, New London, Conn.]
Mallinckrodt has entered into an agreement to sell its nuclear imaging business to IBA Molecular for $690 million, the company said Wednesday. The Hazelwood-based drug manufacturer said it is moving away from nuclear imaging to continue its focus on high-growth specialty pharmaceuticals. The deal affects 800 employees and two manufacturing facilities, including one in Maryland Heights."/>
Mallinckrodt to sell nuclear imaging business [St. Louis Post-Dispatch]
Cesca Therapeutics Inc., an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6,102,941 shares of its common stock. The conversion was effected in accordance with the previously announced purchase agreement entered into between Cesca Therapeutics and Boyalife USA, dated..."/>
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity
Prima BioMed Ltd announces the granting of patent number 2142210 entitled "Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease" by the European Patent Office. The patent relates to Prima's IMP731 antibody. The granted claims provide protection for specific sequences of anti-LAG-3 antibodies and their use in depleting LAG-3+ T cells by complement dependent..."/>
European Patent Grants for IMP731 Antibody
Comcast Corp.' s NBCUniversal division..."/>
M and A Navigator: Deal pipeline –24 August
ProMetic Life Sciences Inc. has agreed to acquire Canadian biotechnology company Telesta Therapeutics, Inc, the company said. Under the terms of the Agreement, ProMetic will acquire all of the share capital of Telesta at a share price of CDN 0.14 payable in ProMetic common shares. The number of common shares to be issued by ProMetic will be based on the volume-weighted average closing price of ProMetic's common shares for the..."/>
ProMetic Agrees to Acquire Canadian Biotechnology Firm Telesta Therapeutics
Mesoblast Limited today reported its consolidated financial results and operational highlights for the three months ended 30 June 2016 and year ended 30 June 2016. Mesoblast ended FY16 with cash reserves of US $80.9 million. The Company reduced its annual operating and investing cash outflows by 15% to US $89.7 million for FY16 in comparison with the prior financial year."/>
Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
Amgen today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter for the New Drug Application for Parsabiv™ for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis. Amgen is reviewing the Complete Response Letter, and we anticipate a post-action meeting with the FDA later this year to discuss the Complete Response."/>
Amgen Provides Update On Status Of Parsabiv™ (Etelcalcetide) New Drug Application (NDA) Submitted To The U.S. Food And Drug Administration (FDA)
Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes, today announced an amendment of its Cooperative Research and Development Agreement with the National Cancer Institute to extend the CRADA for an additional five-year term until 2021. Under the extended CRADA, the Company will continue working with Steven A. Rosenberg, M.D., Ph.D., chief of NCI's Surgery Branch, to develop..."/>
Lion Biotechnologies Announces 5-Year Extension of National Cancer Institute CRADA for Development of Novel TIL Immuno-Oncology Therapies

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary505 Articles
Information Technology493 Articles
Financials372 Articles
Industrials284 Articles
Health Care279 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at